Avadim Technologies, Inc. (“Avadim”), a life sciences company focused on developing pathways to address emerging gaps in global health, announced today record-breaking revenue results for its third quarter 2015. The Company reported consolidated unaudited gross revenue of approximately $1,268,000, which was up 157% over the third quarter 2014 of $493,000. The Company also reported 2015 third quarter revenue increase 45% over second quarter 2015 of $874,000.
Steve Woody, Chairman and CEO of Avadim, said,
“We are very pleased that our third quarter results were as expected.
Our relentless pace of growth is driven by our proven strategy of serving our
customers and stakeholders through innovation of our expanding pathogenesis
based therapy platform. We are well-positioned to continue to deliver long-term
growth.”
The
quarterly estimated gross revenue presented in this release are based on
preliminary financial data and are subject to change until the year-end
financial reporting process is completed.
About Avadim Technologies, Inc.
Avadim Technologies, Inc. is a
life sciences company that has developed a series of Pathogenesis Based
Therapies that optimize stratum corneum and integumentary functions. By
focusing on and protecting and supporting the stratum corneum (the outer layer
of the epidermis) and supporting the natural physiological functions of the
integumentary system (the organ system that consists of the skin, hair, nails,
and exocrine glands), we have developed what we believe to represent a new, advanced
therapeutic class of therapies capable of unlocking pathways to address
emerging gaps in global health.
To learn more about Avadim
Technologies, Inc., visit
No comments:
Post a Comment